Skip to the page

Data / Drug companies / CSL Behring GmbH

CSL Behring GmbH: 12 products in the FDA NDC directory, labeler code 63833

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

CSL Behring GmbH (labeler code 63833) lists 12 products in the FDA National Drug Code Directory, covering 5 finished drugs by generic name. By type: 11 plasma derivatives, 1 prescription drugs. Its main marketing category is biologics (BLA). The newest product started marketing on June 16, 2025.

The request: Watch CSL Behring GmbH (FDA labeler code 63833): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
63833
Products in commercial distribution
12
Packages
12
Finished drugs by generic name
5
Prescription products
1
Over the counter products
0
Flagged as original packager
1 of 1 products that carry the flag
Started marketing in the last 12 months
0
Earliest marketing start
May 1, 1986
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Biologics (BLA)12100%

Products by type

TypeProductsShare
Plasma derivatives1191.7%
Prescription drugs18.3%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

DrugProductsCompanies listing it
Antihemophilic factor/von willebrand factor complex (human)32
Human c1-esterase inhibitor32
Fibrinogen human21
Factor xiii concentrate (human)11
Garadacimab11

Dosage forms

Dosage formProductsShare
Kit975%
Injection, solution216.7%
Injection, powder, lyophilized, for solution18.3%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Andembry63833-925Injection, solutionBiologics (BLA)June 16, 2025
HAEGARDA C1 Esterase Inhibitor Subcutaneous (Human)63833-829KitBiologics (BLA)June 22, 2017
HAEGARDA C1 Esterase Inhibitor Subcutaneous (Human)63833-828KitBiologics (BLA)June 22, 2017
Kcentra63833-387KitBiologics (BLA)December 13, 2013
Kcentra63833-386KitBiologics (BLA)April 29, 2013
Berinert63833-825KitBiologics (BLA)December 22, 2011
Corifact63833-518KitBiologics (BLA)February 17, 2011
Riastap63833-892Injection, solutionBiologics (BLA)January 16, 2009
RiaSTAP63833-891Injection, powder, lyophilized, for solutionBiologics (BLA)January 16, 2009
Humate-P63833-617KitBiologics (BLA)May 1, 1986
Humate-P63833-616KitBiologics (BLA)May 1, 1986
Humate-P63833-615KitBiologics (BLA)May 1, 1986

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.